Novel qPCR-based PrenaTest® successfully validated in clinical study

Konstanz, Germany, December 1, 2015 –LifeCodexx AG reported today the successful validation of its innovative qPCR-based NIPT assay designed to determine fetal trisomy 21 from maternal blood. The blinded study with close to 700 samples demonstrates clearly that the accuracy of the new qPCR-based PrenaTest® is superior to the accuracy of the combined test and comparable to the performance of current non-invasive prenatal tests based on next generation sequencing or microarrays.

Read more

PrenaTest® is now reimbursed by Swiss statutory health insurance programs

Constance, Germany – Now many pregnant women who are insured in Switzerland could benefit from the PrenaTest®. As the first non-invasive prenatal test in Europe for the detection of chromosomal disorders from maternal blood it will be reimbursed by the statutory health insurance (OKP) in Switzerland starting July 15, 2015. This decision was made by the Federal Department of Home Affairs (EDI) on recommendation of the Swiss Federal Office of Public Health (BAG).

Read more

LifeCodexx AG reports successful proof-of-principle of innovative PCR-based NIPT assay

Constance/Germany – LifeCodexx AG today reports the successful outcome of a proof-of-principle of its novel assay for non-invasive prenatal testing (NIPT assay) based on quantitative real-time PCR (qPCR). This NIPT assay, designed to determine fetal aneuploidies from maternal blood, will offer significant advantages, such as enhanced test performance at affordable prices, over other prenatal examination methods. The proof-of-principle study comprised 93 blood samples with eight positive trisomy 21 cases of which the assay unambiguously detected all positive samples.

Read more